AJANTPHARM Stock Overview
A specialty pharmaceutical formulation company, together with its subsidiaries, develops, manufactures, and markets speciality pharmaceutical finished dosages. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
My Notes
Capture your thoughts, links and company narrative
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
Ajanta Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹2,866.45 |
| 52 Week High | ₹3,485.00 |
| 52 Week Low | ₹1,952.00 |
| Beta | 0.14 |
| 1 Month Change | -2.68% |
| 3 Month Change | -8.46% |
| 1 Year Change | 45.64% |
| 3 Year Change | 102.56% |
| 5 Year Change | 348.65% |
| Change since IPO | 18,201.68% |
Recent News & Updates
With EPS Growth And More, Ajanta Pharma (NSE:AJANTPHARM) Makes An Interesting Case
Dec 15
Revenue Beat: Ajanta Pharma Limited Exceeded Revenue Forecasts By 5.3% And Analysts Are Updating Their Estimates
Oct 31Recent updates
With EPS Growth And More, Ajanta Pharma (NSE:AJANTPHARM) Makes An Interesting Case
Dec 15Revenue Beat: Ajanta Pharma Limited Exceeded Revenue Forecasts By 5.3% And Analysts Are Updating Their Estimates
Oct 31Here's Why Ajanta Pharma (NSE:AJANTPHARM) Has Caught The Eye Of Investors
Sep 10We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease
Aug 23Ajanta Pharma Limited Just Recorded A 11% EPS Beat: Here's What Analysts Are Forecasting Next
Aug 04Some Confidence Is Lacking In Ajanta Pharma Limited's (NSE:AJANTPHARM) P/E
Aug 01With EPS Growth And More, Ajanta Pharma (NSE:AJANTPHARM) Makes An Interesting Case
Jun 01Ajanta Pharma Limited (NSE:AJANTPHARM) Analysts Are Pretty Bullish On The Stock After Recent Results
May 05Ajanta Pharma Limited's (NSE:AJANTPHARM) Intrinsic Value Is Potentially 23% Below Its Share Price
Apr 05We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease
Feb 23Ajanta Pharma Limited (NSE:AJANTPHARM) Investors Are Less Pessimistic Than Expected
Dec 23Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly
Aug 26These 4 Measures Indicate That Ajanta Pharma (NSE:AJANTPHARM) Is Using Debt Reasonably Well
Feb 07Here's Why Ajanta Pharma (NSE:AJANTPHARM) Has Caught The Eye Of Investors
Oct 24Estimating The Intrinsic Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)
Aug 25Is Now The Time To Put Ajanta Pharma (NSE:AJANTPHARM) On Your Watchlist?
Jul 19A Look At The Intrinsic Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)
Apr 28Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly
Mar 14I Built A List Of Growing Companies And Ajanta Pharma (NSE:AJANTPHARM) Made The Cut
Feb 06Estimating The Fair Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)
Dec 13Ajanta Pharma (NSE:AJANTPHARM) Will Pay A Dividend Of ₹9.50
Oct 31Here's Why We Think Ajanta Pharma (NSE:AJANTPHARM) Is Well Worth Watching
Sep 22Is Ajanta Pharma Limited (NSE:AJANTPHARM) Trading At A 27% Discount?
Sep 08Does Ajanta Pharma (NSE:AJANTPHARM) Have A Healthy Balance Sheet?
Aug 26Here's Why Shareholders Will Not Be Complaining About Ajanta Pharma Limited's (NSE:AJANTPHARM) CEO Pay Packet
Jul 07Should You Be Adding Ajanta Pharma (NSE:AJANTPHARM) To Your Watchlist Today?
Jun 14Is Ajanta Pharma Limited (NSE:AJANTPHARM) Trading At A 30% Discount?
May 15Ajanta Pharma Limited (NSE:AJANTPHARM) Vies For A Place In Your Dividend Portfolio: Here's Why
Apr 10Ajanta Pharma Limited's (NSE:AJANTPHARM) Has Had A Decent Run On The Stock market: Are Fundamentals In The Driver's Seat?
Mar 11Does Ajanta Pharma (NSE:AJANTPHARM) Deserve A Spot On Your Watchlist?
Feb 24The Ajanta Pharma (NSE:AJANTPHARM) Share Price Is Up 56% And Shareholders Are Holding On
Jan 30
What Can We Make Of Ajanta Pharma's (NSE:AJANTPHARM) CEO Compensation?
Jan 18Shareholder Returns
| AJANTPHARM | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 2.1% | 0.8% | -4.2% |
| 1Y | 45.6% | 39.7% | 19.1% |
Return vs Industry: AJANTPHARM exceeded the Indian Pharmaceuticals industry which returned 39.7% over the past year.
Return vs Market: AJANTPHARM exceeded the Indian Market which returned 19.1% over the past year.
Price Volatility
| AJANTPHARM volatility | |
|---|---|
| AJANTPHARM Average Weekly Movement | 4.7% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: AJANTPHARM has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: AJANTPHARM's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1973 | 8,073 | Yogesh Agrawal | www.ajantapharma.com |
Ajanta Pharma Limited, a specialty pharmaceutical formulation company, together with its subsidiaries, develops, manufactures, and markets speciality pharmaceutical finished dosages. The company markets and serves various therapeutic segments, such as cardiology, antidiabetic, ophthalmology, dermatology, pain management, and respiratory areas. It also provides tablets, capsules, injectables, inhalers, ointments, creams, and liquids.
Ajanta Pharma Limited Fundamentals Summary
| AJANTPHARM fundamental statistics | |
|---|---|
| Market cap | ₹357.98b |
| Earnings (TTM) | ₹8.75b |
| Revenue (TTM) | ₹44.91b |
40.9x
P/E Ratio8.0x
P/S RatioIs AJANTPHARM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AJANTPHARM income statement (TTM) | |
|---|---|
| Revenue | ₹44.91b |
| Cost of Revenue | ₹11.43b |
| Gross Profit | ₹33.48b |
| Other Expenses | ₹24.73b |
| Earnings | ₹8.75b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 70.06 |
| Gross Margin | 74.56% |
| Net Profit Margin | 19.48% |
| Debt/Equity Ratio | 0.07% |
How did AJANTPHARM perform over the long term?
See historical performance and comparisonDividends
2.0%
Current Dividend Yield78%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 05:47 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Ajanta Pharma Limited is covered by 25 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nikhil Mathur | Ambit Capital |
| null null | Anand Rathi Shares and Stock Brokers Limited |
| Rashmi Sancheti Shetty | Anand Rathi Shares and Stock Brokers Limited |